Biophan Technologies CEO Michael Weiner to Present at BIOCOM Nanotechnology Conference in San Diego.

ROCHESTER, N.Y. -- CEO to Address Gathering Entitled, "Nanotechnology: Commercializing the Dream"

Biophan Technologies, Inc. (OTC BB: BIPH), a developer of next-generation biomedical technology, has announced that Company CEO Michael Weiner will participate in a panel discussion with other nanotechnology industry leaders at the BIOCOM Conference entitled "Nanotechnology: Commercializing the Dream," in San Diego, CA, November 18th-19th.

"It pleases us greatly that Biophan is being recognized by organizations such as BIOCOM as one of the leaders in pragmatic industrial uses of nanotechnology," said Mr. Weiner. BIOCOM is the largest regional life sciences association in the world made up of more than 450 leading life sciences companies and organizations from the Greater San Diego and Southern California region. At the conference, Mr. Weiner will describe some of Biophan's proprietary nanotechnology-based solutions for biomedical devices, as well as nanotechnology innovation and opportunities in the health care sector.

Biophan's nanotechnology is currently the focus of two joint development projects; one with Boston Scientific (NYSE:BSX) relating to MRI safety and image compatibility and another with NASA relating to implantable power systems fueled by body heat for longer battery life.

"The Biomedical device industry is growing rapidly, but most devices that ship have limitations and restrictions working with MRI," said Mr. Weiner. He continued, "Our nanotechnology solutions have been demonstrated to reduce the image artifacts associated with most devices and our anti-antenna and filtering technologies contribute to making the devices safe for use with MRI."

"I welcome the opportunity to describe Biophan's important contributions to the medical device industry, as millions of people with pacemakers, defibrillators and neurostimulators are affected by problems of MRI safety and image compatibility," stated Mr. Weiner.

Biophan owns or exclusively licenses over 100 U.S. issued and pending patents, in addition to many corresponding foreign filings. Once it meets certain capital requirements, it plans to apply for listing on a major stock exchange.

Additional information and previous presentations that Mr. Weiner has given about Biophan's nanotechnology initiatives can be viewed online at http://www.biophan.com/presentations/RPI.html or http://www.biophan.com/presentations/RPI.ppt. Information about Biophan innovations in MRI-guided surgery can be viewed at http://www.biophan.com/pr/080904NanosetWebsite_and_print.html.

About BIOCOM

BIOCOM is a diverse association of more than 450 leading companies and organizations in the life sciences sector from the Greater San Diego and Southern California region. The largest regional life sciences/biotech organization in the world, BIOCOM strives to accelerate the life sciences field and the Southern California biotech industry through a range of efforts, including public policy advocacy in legislative, regulatory and public affairs agendas at the local, state and federal levels; financial capital development; and enhancement of networking and information exchange throughout the industry. For further information about this conference, please visit http://www.biocom.org/events/eventdetails.asp?eventid=771.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan product lines include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors have a total of 101 U.S. patents issued, pending or allowed. This total includes 22 issued U.S. patents, 11 recently-allowed applications that will issue as patents in the near future, and 68 pending applications at various stages of examination at the U.S. Patent and Trademark Office, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.